Marshall Wace LLP Purchases 3,864,908 Shares of Edwards Lifesciences Corporation $EW

Marshall Wace LLP increased its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 127.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 6,895,579 shares of the medical research company’s stock after buying an additional 3,864,908 shares during the period. Edwards Lifesciences accounts for approximately 0.6% of Marshall Wace LLP’s holdings, making the stock its 16th biggest position. Marshall Wace LLP owned about 1.17% of Edwards Lifesciences worth $539,303,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC bought a new position in shares of Edwards Lifesciences in the fourth quarter worth about $266,000. Federated Hermes Inc. increased its position in Edwards Lifesciences by 128.2% in the 1st quarter. Federated Hermes Inc. now owns 2,592 shares of the medical research company’s stock worth $188,000 after buying an additional 1,456 shares during the period. Costello Asset Management INC acquired a new position in shares of Edwards Lifesciences during the first quarter worth approximately $29,000. Cary Street Partners Investment Advisory LLC boosted its position in shares of Edwards Lifesciences by 71.5% in the first quarter. Cary Street Partners Investment Advisory LLC now owns 1,034 shares of the medical research company’s stock valued at $75,000 after acquiring an additional 431 shares during the period. Finally, Wealthspire Advisors LLC grew its stake in shares of Edwards Lifesciences by 6.5% in the first quarter. Wealthspire Advisors LLC now owns 10,379 shares of the medical research company’s stock worth $752,000 after acquiring an additional 630 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $83.08, for a total value of $1,080,040.00. Following the completion of the transaction, the chief financial officer owned 39,898 shares in the company, valued at approximately $3,314,725.84. The trade was a 24.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Daniel J. Lippis sold 1,020 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $82.55, for a total value of $84,201.00. Following the completion of the transaction, the vice president directly owned 22,002 shares in the company, valued at $1,816,265.10. The trade was a 4.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 1.29% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on EW. Robert W. Baird set a $83.00 price target on shares of Edwards Lifesciences in a report on Friday, October 31st. Piper Sandler reiterated an “overweight” rating and issued a $95.00 target price (up previously from $90.00) on shares of Edwards Lifesciences in a research note on Friday, October 31st. Canaccord Genuity Group restated a “hold” rating on shares of Edwards Lifesciences in a research note on Friday. Truist Financial upped their price target on Edwards Lifesciences from $87.00 to $90.00 and gave the company a “hold” rating in a report on Monday, November 3rd. Finally, Barclays reiterated an “overweight” rating and issued a $99.00 price objective (up previously from $95.00) on shares of Edwards Lifesciences in a research report on Friday, October 31st. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $91.52.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $85.72 on Friday. The business has a 50 day simple moving average of $80.75 and a 200 day simple moving average of $78.68. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29. The company has a market capitalization of $49.74 billion, a PE ratio of 36.95, a price-to-earnings-growth ratio of 3.72 and a beta of 0.97. Edwards Lifesciences Corporation has a one year low of $65.94 and a one year high of $87.40.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The company had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same period last year, the business earned $0.67 earnings per share. The business’s revenue was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, sell-side analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.